Cytokinetics Announces Initiation of Phase I Clinical Trial of Oral ... MarketWatch (press release) An intravenous formulation of omecamtiv mecarbil, a novel cardiac muscle myosin activator, is currently being evaluated in the ATOMIC-AHF (A Trial of Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure) clinical trial. |
